Predicting positron emission tomography brain amyloid positivity using interpretable machine learning models with wearable sensor data and lifestyle factors.
Amyloid positivity
Lifestyle factors
Machine learning
Mild cognitive impairment
PiB-PET
Wearable sensor
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
12 Dec 2023
12 Dec 2023
Historique:
received:
18
04
2023
accepted:
29
11
2023
medline:
13
12
2023
pubmed:
13
12
2023
entrez:
13
12
2023
Statut:
epublish
Résumé
Developing a screening method for identifying individuals at higher risk of elevated brain amyloid burden is important to reduce costs and burden to patients in clinical trials on Alzheimer's disease or the clinical setting. We developed machine learning models using objectively measured lifestyle factors to predict elevated brain amyloid burden on positron emission tomography. Our prospective cohort study of non-demented, community-dwelling older adults aged ≥ 65 years was conducted from August 2015 to September 2019 in Usuki, Oita Prefecture, Japan. One hundred and twenty-two individuals with mild cognitive impairment or subjective memory complaints (54 men and 68 women, median age: 75.50 years) wore wearable sensors and completed self-reported questionnaires, cognitive test, and positron emission tomography imaging at baseline. Moreover, 99 individuals in the second year and 61 individuals in the third year were followed up. In total, 282 eligible records with valid wearable sensors, cognitive test results, and amyloid imaging and data on demographic characteristics, living environments, and health behaviors were used in the machine learning models. Amyloid positivity was defined as a standardized uptake value ratio of ≥ 1.4. Models were constructed using kernel support vector machine, Elastic Net, and logistic regression for predicting amyloid positivity. The mean score among 10 times fivefold cross-validation repeats was utilized for evaluation. In Elastic Net, the mean area under the receiver operating characteristic curve of the model using objectively measured lifestyle factors alone was 0.70, whereas that of the models using wearable sensors in combination with demographic characteristics and health and life environment questionnaires was 0.79. Moreover, 22 variables were common to all machine learning models. Our machine learning models are useful for predicting elevated brain amyloid burden using readily-available and noninvasive variables without the need to visit a hospital. This prospective study was conducted in accordance with the Declaration of Helsinki and was approved by the local ethics committee of Oita University Hospital (UMIN000017442). A written informed consent was obtained from all participants. This research was performed based on the Strengthening the Reporting of Observational Studies in Epidemiology reporting guideline.
Sections du résumé
BACKGROUND
BACKGROUND
Developing a screening method for identifying individuals at higher risk of elevated brain amyloid burden is important to reduce costs and burden to patients in clinical trials on Alzheimer's disease or the clinical setting. We developed machine learning models using objectively measured lifestyle factors to predict elevated brain amyloid burden on positron emission tomography.
METHODS
METHODS
Our prospective cohort study of non-demented, community-dwelling older adults aged ≥ 65 years was conducted from August 2015 to September 2019 in Usuki, Oita Prefecture, Japan. One hundred and twenty-two individuals with mild cognitive impairment or subjective memory complaints (54 men and 68 women, median age: 75.50 years) wore wearable sensors and completed self-reported questionnaires, cognitive test, and positron emission tomography imaging at baseline. Moreover, 99 individuals in the second year and 61 individuals in the third year were followed up. In total, 282 eligible records with valid wearable sensors, cognitive test results, and amyloid imaging and data on demographic characteristics, living environments, and health behaviors were used in the machine learning models. Amyloid positivity was defined as a standardized uptake value ratio of ≥ 1.4. Models were constructed using kernel support vector machine, Elastic Net, and logistic regression for predicting amyloid positivity. The mean score among 10 times fivefold cross-validation repeats was utilized for evaluation.
RESULTS
RESULTS
In Elastic Net, the mean area under the receiver operating characteristic curve of the model using objectively measured lifestyle factors alone was 0.70, whereas that of the models using wearable sensors in combination with demographic characteristics and health and life environment questionnaires was 0.79. Moreover, 22 variables were common to all machine learning models.
CONCLUSION
CONCLUSIONS
Our machine learning models are useful for predicting elevated brain amyloid burden using readily-available and noninvasive variables without the need to visit a hospital.
TRIAL REGISTRATION
BACKGROUND
This prospective study was conducted in accordance with the Declaration of Helsinki and was approved by the local ethics committee of Oita University Hospital (UMIN000017442). A written informed consent was obtained from all participants. This research was performed based on the Strengthening the Reporting of Observational Studies in Epidemiology reporting guideline.
Identifiants
pubmed: 38087316
doi: 10.1186/s13195-023-01363-x
pii: 10.1186/s13195-023-01363-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
212Informations de copyright
© 2023. The Author(s).
Références
van Dyck CH, Sabbagh M, Cohen S. Lecanemab in Early Alzheimer’s Disease. Reply N Engl J Med. 2023;388(17):1631–2. https://doi.org/10.1056/NEJMoa2212948 .
doi: 10.1056/NEJMoa2212948
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–29. https://doi.org/10.1016/S1474-4422(14)70090-0 .
doi: 10.1016/S1474-4422(14)70090-0
pubmed: 24849862
Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Paul S, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207–16. https://doi.org/10.1016/S1474-4422(12)70291-0 .
doi: 10.1016/S1474-4422(12)70291-0
pubmed: 23332364
pmcid: 3622225
Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795–804. https://doi.org/10.1056/NEJMoa1202753 .
doi: 10.1056/NEJMoa1202753
pubmed: 22784036
pmcid: 3474597
Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184–5. https://doi.org/10.1126/science.1566067 .
doi: 10.1126/science.1566067
pubmed: 1566067
Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537(7618):50–6. https://doi.org/10.1038/nature19323 .
doi: 10.1038/nature19323
pubmed: 27582220
Golde TE. Disease-modifying therapies for Alzheimer’s disease: more questions than answers. Neurotherapeutics. 2022;19(1):209–27. https://doi.org/10.1007/s13311-022-01201-2 .
doi: 10.1007/s13311-022-01201-2
pmcid: 8885119
Gauthier S, Albert M, Fox N, Goedert M, Kivipelto M, Mestre-Ferrandiz J, et al. Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 2016;12(1):60–4. https://doi.org/10.1016/j.jalz.2015.12.003 .
doi: 10.1016/j.jalz.2015.12.003
pubmed: 26710325
Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68(11):1404–11. https://doi.org/10.1001/archneurol.2011.150 .
doi: 10.1001/archneurol.2011.150
pubmed: 21747008
Roberts RO, Aakre JA, Kremers WK, Vassilaki M, Knopman DS, Mielke MM, et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting. JAMA Neurol. 2018;75(8):970–9. https://doi.org/10.1001/jamaneurol.2018.0629 .
doi: 10.1001/jamaneurol.2018.0629
pubmed: 29710225
pmcid: 6142936
Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J, et al. A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study. Mol Psychiatry. 2014;19(4):519–26. https://doi.org/10.1038/mp.2013.40 .
doi: 10.1038/mp.2013.40
pubmed: 23628985
Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL, et al. Associations of plasma phospho-tau217 levels with tau positron emission tomography in early alzheimer disease. JAMA Neurol. 2021;78(2):149–56. https://doi.org/10.1001/jamaneurol.2020.4201 .
doi: 10.1001/jamaneurol.2020.4201
pubmed: 33165506
Janelidze S, Teunissen CE, Zetterberg H, Allué JA, Sarasa L, Eichenlaub U, et al. Head-to-head comparison of 8 plasma amyloid-β 42/40 assays in alzheimer disease. JAMA Neurol. 2021;78(11):1375–82. https://doi.org/10.1001/jamaneurol.2021.3180 .
doi: 10.1001/jamaneurol.2021.3180
pubmed: 34542571
Udeh-Momoh C, Zheng B, Sandebring-Matton A, Novak G, Kivipelto M, Jönsson L, et al. Blood derived amyloid biomarkers for alzheimer’s disease prevention. J Prev Alzheimers Dis. 2022;9(1):12–21. https://doi.org/10.14283/jpad.2021.70 .
doi: 10.14283/jpad.2021.70
pubmed: 35098969
Buchman AS, Boyle PA, Yu L, Shah RC, Wilson RS, Bennett DA. Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology. 2012;78(17):1323–9. https://doi.org/10.1212/WNL.0b013e3182535d35 .
doi: 10.1212/WNL.0b013e3182535d35
pubmed: 22517108
pmcid: 3335448
Blackwell T, Yaffe K, Laffan A, Ancoli-Israel S, Redline S, Ensrud KE, Osteoporotic fractures in men (MrOS) study group, et al. Associations of objectively and subjectively measured sleep quality with subsequent cognitive decline in older community dwelling men: the MrOS sleep study. Sleep. 2014;37(4):655–63. https://doi.org/10.5665/sleep.3562 .
doi: 10.5665/sleep.3562
pubmed: 24899757
pmcid: 4044750
James C, Ranson JM, Everson R, Llewellyn DJ. Performance of machine learning algorithms for predicting progression to dementia in memory clinic patients. JAMA Netw Open. 2021;4(12): e2136553. https://doi.org/10.1001/jamanetworkopen.2021.36553 .
doi: 10.1001/jamanetworkopen.2021.36553
pubmed: 34913981
pmcid: 8678688
Gupta A, Kahali B. Machine learning-based cognitive impairment classification with optimal combination of neuropsychological tests. Alzheimers Dement (N Y). 2020;6(1): e12049. https://doi.org/10.1002/trc2.12049 .
doi: 10.1002/trc2.12049
pubmed: 32699817
Sato K, Ihara R, Suzuki K, Niimi Y, Toda T, Jimenez-Maggiora G, et al. Predicting amyloid risk by machine learning algorithms based on the A4 screen data: application to the Japanese trial-ready cohort study. Alzheimers Dement (N Y). 2021;7(1):e12135. https://doi.org/10.1002/trc2.12135 .
doi: 10.1002/trc2.12135
pubmed: 33778148
Ko H, Ihm JJ, Kim HG, Alzheimer’s Disease Neuroimaging Initiative. Cognitive profiling related to cerebral amyloid beta burden using machine learning approaches. Front Aging Neurosci. 2019;11:95. https://doi.org/10.3389/fnagi.2019.00095 .
doi: 10.3389/fnagi.2019.00095
pubmed: 31105554
pmcid: 6499028
Insel PS, Palmqvist S, Mackin RS, Nosheny RL, Hansson O, Weiner MW, et al. Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information. Alzheimers Dement (Amst). 2016;4:76–84. https://doi.org/10.1016/j.dadm.2016.07.002 .
doi: 10.1016/j.dadm.2016.07.002
pubmed: 27722193
Ezzati A, Harvey DJ, Habeck C, Golzar A, Qureshi IA, Zammit AR, et al. Predicting amyloid-β levels in amnestic mild cognitive impairment using machine learning techniques. J Alzheimers Dis. 2020;73:1211–9. https://doi.org/10.3233/JAD-191038 .
doi: 10.3233/JAD-191038
pubmed: 31884486
pmcid: 7376527
Palmqvist S, Insel PS, Zetterberg H, Blennow K, Brix B, Stomrud E, et al. Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer’s disease: cross-validation study of practical algorithms. Alzheimers Dement. 2019;15(2):194–204. https://doi.org/10.1016/j.jalz.2018.08.014 .
doi: 10.1016/j.jalz.2018.08.014
pubmed: 30365928
pmcid: 6374284
Lee JH, Byun MS, Yi D, Sohn BK, Jeon SY, Lee Y, et al. Prediction of cerebral amyloid with common information obtained from memory clinic practice. Front Aging Neurosci. 2018;10:309. https://doi.org/10.3389/fnagi.2018.0030 .
doi: 10.3389/fnagi.2018.0030
pubmed: 30337868
pmcid: 6178978
Kim JP, Kim J, Jang H, Kim J, Kang SH, Kim JS, et al. Predicting amyloid positivity in patients with mild cognitive impairment using a radiomics approach. Sci Rep. 2021;11(1):6954. https://doi.org/10.1038/s41598-021-86114-4 .
doi: 10.1038/s41598-021-86114-4
pubmed: 33772041
pmcid: 7997887
Youn YC, Kim HR, Shin H, Jeong H, Han S, Pyun J, et al. Prediction of amyloid PET positivity via machine learning algorithms trained with EDTA-based blood amyloid-β oligomerization data. BMC Med Inform Decis Mak. 2022;22(1):286. https://doi.org/10.1186/s12911-022-02024-z .
doi: 10.1186/s12911-022-02024-z
pubmed: 36344984
pmcid: 9641916
Langford O, Raman R, Sperling RA, Cummings J, Sun CK, Jimenez-Maggiora G, et al. Predicting amyloid burden to accelerate recruitment of secondary prevention clinical trials. J Prev Alzheimers Dis. 2020;7(4):213–8. https://doi.org/10.14283/jpad.2020.44 .
doi: 10.14283/jpad.2020.44
pmcid: 7745538
Ju YE, McLeland JS, Toedebusch CD, Xiong C, Fagan AM, Duntley SP, et al. Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 2013;70(5):587–93. https://doi.org/10.1001/jamaneurol.2013.2334 .
doi: 10.1001/jamaneurol.2013.2334
pubmed: 23479184
pmcid: 3676720
Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol. 2004;3(6):343–53. https://doi.org/10.1016/S1474-4422(04)00767-7 .
doi: 10.1016/S1474-4422(04)00767-7
pubmed: 15157849
Daviglus ML, Plassman BL, Pirzada A, Bell CC, Bowen PE, Burke JR, et al. Risk factors and preventive interventions for Alzheimer disease: state of the science. Arch Neurol. 2011;68(9):1185–90. https://doi.org/10.1001/archneurol.2011.100 .
doi: 10.1001/archneurol.2011.100
pubmed: 21555601
Kimura N, Aso Y, Yabuuchi K, Ishibashi M, Hori D, Sasaki Y, et al. Modifiable lifestyle factors and cognitive function in older people: a cross-sectional observational study. Front Neurol. 2019;10:401. https://doi.org/10.3389/fneur.2019.00401 .
doi: 10.3389/fneur.2019.00401
pubmed: 31068892
pmcid: 6491512
Kimura N, Aso Y, Yabuuchi K, Ishibashi M, Hori D, Sasaki Y, et al. Association of modifiable lifestyle factors with cortical amyloid burden and cerebral glucose metabolism in older adults with mild cognitive impairment. JAMA Netw Open. 2020;3(6):e205719. https://doi.org/10.1001/jamanetworkopen.2020.5719 .
doi: 10.1001/jamanetworkopen.2020.5719
pubmed: 32515796
pmcid: 7284299
Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA. 1995;273(5):402–7. https://doi.org/10.1001/jama.273.5.402 .
doi: 10.1001/jama.273.5.402
pubmed: 7823386
Eguchi A, Kimura N, Aso Y, Yabuuchi K, Ishibashi M, Hori D, et al. Relationship between the Japanese version of the Montreal cognitive assessment and PET imaging in subjects with mild cognitive impairment. Curr Alzheimer Res. 2019;16(9):852–60. https://doi.org/10.2174/1567205016666190805155230 .
doi: 10.2174/1567205016666190805155230
pubmed: 31385770
Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122–31. https://doi.org/10.1002/ana.21843 .
doi: 10.1002/ana.21843
pubmed: 20186853
pmcid: 2830375
Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, Ellis KA, et al. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology. 2011;76(12):1091–8. https://doi.org/10.1212/WNL.0b013e318211c352 .
doi: 10.1212/WNL.0b013e318211c352
pubmed: 21422459
Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain. 2008;131(Pt 3):665–80. https://doi.org/10.1093/brain/awm336 .
doi: 10.1093/brain/awm336
pubmed: 18263627
Rodriguez-Vieitez E, Leuzy A, Chiotis K, Saint-Aubert L, Wall A, Nordberg A, et al. Comparability of [18F]THK5317 and [11C]PIB blood flow proxy images with [18F]FDG positron emission tomography in Alzheimer’s disease. J Cereb Blood Flow Metab. 2017;37(2):740–9.
doi: 10.1177/0271678X16645593
pubmed: 27107028
Kursa MB, Rudnicki WR. Feature Selection with the Boruta Package. J Stat Softw. 2010;36(11):1–13. https://doi.org/10.18637/jss.v036.i11 .
doi: 10.18637/jss.v036.i11
Fisher A, Rudin C, Dominici F. All models are wrong, but many are useful: learning a variable’s importance by studying an entire class of prediction models simultaneously. J Machine Learn Res. 2019;20:1–81.
Chen T, Narazaki K, Honda T, Chen S, Haeuchi Y, Nofuji YY, et al. Tri-axial accelerometer-determined daily physical activity and sedentary behavior of suburban community-dwelling older Japanese adults. J Sports Sci Med. 2015;14(3):507–14.
pubmed: 26336336
pmcid: 4541113
Kim M. Association between objectively measured sleep quality and obesity in community-dwelling adults aged 80 years or older: a cross-sectional study. J Korean Med Sci. 2015;30(2):199–206. https://doi.org/10.3346/jkms.2015.30.2.199 .
doi: 10.3346/jkms.2015.30.2.199
pubmed: 25653493
pmcid: 4310948
Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Knopman DS, Lowe V, et al. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: a cross-sectional study. Lancet Neurol. 2017;16(6):435–44. https://doi.org/10.1016/S1474-4422(17)30077-7 .
doi: 10.1016/S1474-4422(17)30077-7
pubmed: 28456479
pmcid: 5516534
Weakley A, Williams JA, Schmitter-Edgecombe M, Cook DJ. Neuropsychological test selection for cognitive impairment classification: a machine learning approach. J Clin Exp Neuropsychol. 2015;37:899–916. https://doi.org/10.1080/13803395.2015.1067290 .
doi: 10.1080/13803395.2015.1067290
pubmed: 26332171
pmcid: 4809360
Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry. 1998;55:809–15. https://doi.org/10.1001/archpsyc.55.9.809 .
doi: 10.1001/archpsyc.55.9.809
pubmed: 9736007
Gottesman RF, Schneider AL, Zhou Y, Chen X, Green E, Gupta N, et al. The ARIC-PET amyloid imaging study: brain amyloid differences by age, race, sex, and APOE. Neurology. 2016;87:473–80. https://doi.org/10.1212/WNL.0000000000002914 .
doi: 10.1212/WNL.0000000000002914
pubmed: 27371485
pmcid: 4970663
Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313:1924–38. https://doi.org/10.1001/jama.2015.4668 .
doi: 10.1001/jama.2015.4668
pubmed: 25988462
pmcid: 4486209
Roe CM, Mintun MA, D’Angelo G, Xiong C, Grant EA, Morris JC. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh compound B uptake. Arch Neurol. 2008;65:1467–71. https://doi.org/10.1001/archneur.65.11.1467 .
doi: 10.1001/archneur.65.11.1467
pubmed: 19001165
pmcid: 2752218
Meng X, D’Arcy C. Education and dementia in the context of the cognitive reserve hypothesis: a systematic review with meta-analyses and qualitative analyses. PLoS One. 2012;7:e38268. https://doi.org/10.1371/journal.pone.0038268 .
doi: 10.1371/journal.pone.0038268
pubmed: 22675535
pmcid: 3366926
Rentz DM, Locascio JJ, Becker JA, Moran EK, Eng E, Buckner RL, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol. 2010;67:353–64. https://doi.org/10.1002/ana.21904 .
doi: 10.1002/ana.21904
pubmed: 20373347
Jack CR Jr, Wiste HJ, Weigand SD, Knopman DS, Vemuri P, Mielke MM, et al. Age, sex, and APOE epsilon4 effects on memory, brain structure, and beta-amyloid across the adult life span. JAMA Neurol. 2015;72:511–9. https://doi.org/10.1001/jamaneurol.2014.4821 .
doi: 10.1001/jamaneurol.2014.4821
pmcid: 4428984
Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry. 2005;62:685–91. https://doi.org/10.1001/archpsyc.62.6.685 .
doi: 10.1001/archpsyc.62.6.685
pubmed: 15939846
Rabin JS, Shirzadi Z, Swardfager W, MacIntosh BJ, Schultz A, Yang HS, et al. Amyloid-beta burden predicts prospective decline in body mass index in clinically normal adults. Neurobiol Aging. 2020;93:124–30. https://doi.org/10.1016/j.neurobiolaging.2020.03.002 .
doi: 10.1016/j.neurobiolaging.2020.03.002
pubmed: 32249013
pmcid: 7429980
Vineeth T, Austin M, Yi S, Shaney F, Aylin D, John CM, et al. Higher body mass index is associated with lower cortical amyloid-β burden in cognitively normal individuals in late-life. J Alzheimers Dis. 2019;69:817–27. https://doi.org/10.3233/JAD-190154 .
doi: 10.3233/JAD-190154
Stampfer MJ, Kang JH, Chen J, Cherry R, Grodstein F. Effects of moderate alcohol consumption on cognitive function in women. N Engl J Med. 2005;352(3):245–53. https://doi.org/10.1056/NEJMoa041152 .
doi: 10.1056/NEJMoa041152
pubmed: 15659724
Kim JW, Byun MS, Yi D, Lee JH, Ko K, Jeon SY, et al. Association of moderate alcohol intake with in vivo amyloid-beta deposition in human brain: a cross-sectional study. PLoS Med. 2020;17(2):e1003022. https://doi.org/10.1371/journal.pmed.1003022 .
doi: 10.1371/journal.pmed.1003022
pubmed: 32097439
pmcid: 7041799
Gottesman RF, Schneider AL, Zhou Y, Coresh J, Green E, Gupta N, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317:1443–50. https://doi.org/10.1001/jama.2017.3090 .
doi: 10.1001/jama.2017.3090
pubmed: 28399252
pmcid: 5921896
Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci. 2011;12(12):723–38. https://doi.org/10.1038/nrn3114 .
doi: 10.1038/nrn3114
pubmed: 22048062
pmcid: 4036520
Moran C, Beare R, Phan TG, Bruce DG, Callisaya ML, Srikanth V, et al. Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology. 2015;85(13):1123–30. https://doi.org/10.1212/WNL.0000000000001982 .
doi: 10.1212/WNL.0000000000001982
pubmed: 26333802
pmcid: 5573049
Reed BR, Marchant NL, Jagust WJ, DeCarli CC, Mack W, Chui HC. Coronary risk correlates with cerebral amyloid deposition. Neurobiol Aging. 2012;33(9):1979–87. https://doi.org/10.1016/j.neurobiolaging.2011.10.002 .
doi: 10.1016/j.neurobiolaging.2011.10.002
pubmed: 22078485
Irina A, Seppo H, Arto M, Paavo R Sr, Hilkka S. Beta-amyloid load is not influenced by the severity of cardiovascular disease in aged and demented patients. Stroke. 1999;30(3):613–8. https://doi.org/10.1161/01.str.30.3.613 .
doi: 10.1161/01.str.30.3.613
pubmed: 10066860
Hulette CM, Welsh-Bohmer K. Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology. 2007;68(6):471. https://doi.org/10.1212/01.wnl.0000256286.78188.dd .
doi: 10.1212/01.wnl.0000256286.78188.dd
Choi HJ, Byun MS, Yi D, Sohn BK, Lee JH, Lee J, et al. Associations of thyroid hormone serum levels with in-vivo Alzheimer’s disease pathologies. Alzheimers Res Ther. 2017;9(1):64. https://doi.org/10.1186/s13195-017-0291-5 .
doi: 10.1186/s13195-017-0291-5
pubmed: 28818092
pmcid: 5561599
Belandia B, Latasa MJ, Villa A, Pascual A. Thyroid hormone negatively regulates the transcriptional activity of the beta-amyloid precursor protein gene. J Biol Chem. 1998;273(46):30366–71. https://doi.org/10.1074/jbc.273.46.30366 .
doi: 10.1074/jbc.273.46.30366
pubmed: 9804800
Belakavadi M, Dell J, Grover GJ, Fondell JD. Thyroid hormone suppression of β-amyloid precursor protein gene expression in the brain involves multiple epigenetic regulatory events. Mol Cell Endocrinol. 2011;339(1–2):72–80. https://doi.org/10.1016/j.mce.2011.03.016 .
doi: 10.1016/j.mce.2011.03.016
pubmed: 21458529
Liang KY, Mintun MA, Fagan AM, Goate AM, Bugg JM, Holtzman DM, et al. Exercise and Alzheimer’s disease biomarkers in cognitively normal older adults. Ann Neurol. 2010;68(3):311–8. https://doi.org/10.1002/ana.22096 .
doi: 10.1002/ana.22096
pubmed: 20818789
pmcid: 2936720
Brown BM, Peiffer J, Rainey-Smith SR. Exploring the relationship between physical activity, beta-amyloid and tau: a narrative review. Ageing Res Rev. 2019;50:9–18. https://doi.org/10.1016/j.arr.2019.01.003 .
doi: 10.1016/j.arr.2019.01.003
pubmed: 30615936
Moore KM, Girens RE, Larson SK, Jones MR, Restivo JL, Holtzman DM, et al. A spectrum of exercise training reduces soluble Aβ in a dose-dependent manner in a mouse model of Alzheimer’s disease. Neurobiol Dis. 2016;85:218–24. https://doi.org/10.1016/j.nbd.2015.11.004 .
doi: 10.1016/j.nbd.2015.11.004
pubmed: 26563933
Keage HA, Banks S, Yang KL, Morgan K, Brayne C, Matthews FE. What sleep characteristics predict cognitive decline in the elderly? Sleep Med. 2012;13(7):886–92. https://doi.org/10.1016/j.sleep.2012.02.003 .
doi: 10.1016/j.sleep.2012.02.003
pubmed: 22560827
Foley D, Monjan A, Masaki K, Ross W, Havlik R, White L, et al. Daytime sleepiness is associated with 3-year incident dementia and cognitive decline in older Japanese-American men. J Am Geriatr Soc. 2001;49(12):1628–32. https://doi.org/10.1046/j.1532-5415.2001.t01-1-49271.x .
doi: 10.1046/j.1532-5415.2001.t01-1-49271.x
pubmed: 11843995
Imahori Y, Vetrano DL, Xia X, Grande G, Ljungman P, Fratiglioni L, et al. Association of resting heart rate with cognitive decline and dementia in older adults: a population-based cohort study. Alzheimers Dement. 2022;18(10):1779–87. https://doi.org/10.1002/alz.12495 .
doi: 10.1002/alz.12495
pubmed: 34859936
Kuiper JS, Zuidersma M, Oude Voshaar RC, Zuidema SU, Heuvel ER, Stolk RP, et al. Social relationships and risk of dementia: a systematic review and meta-analysis of longitudinal cohort studies. Ageing Res Rev. 2015;22:39–57. https://doi.org/10.1016/j.arr.2015.04.006 .
doi: 10.1016/j.arr.2015.04.006
Marioni RE, Proust-Lima C, Amieva H, Brayne C, Matthews FE, Dartigues J, et al. Social activity, cognitive decline and dementia risk: a 20-year prospective cohort study. BMC Public Health. 2015;15:1089. https://doi.org/10.1186/s12889-015-2426-6 .
doi: 10.1186/s12889-015-2426-6
pubmed: 26499254
pmcid: 4619410
Donovan NJ, Okereke OI, Vannini P, Amariglio RE, Rentz DM, Marshall GA, et al. Association of higher cortical amyloid burden with loneliness in cognitively normal older adults. JAMA Psychiat. 2016;73(12):1230–7. https://doi.org/10.1001/jamapsychiatry.2016.2657 .
doi: 10.1001/jamapsychiatry.2016.2657
Chihuri S, Mielenz TJ, DiMaggio CJ, Betz ME, DiGuiseppi C, Jones VC, et al. Driving cessation and health outcomes in older adults. J Am Geriatr Soc. 2016;64(2):332–41. https://doi.org/10.1111/jgs.13931 .
doi: 10.1111/jgs.13931
pubmed: 26780879
pmcid: 5021147
Sanford S, Naglie G, Cameron D, Rapoport MJ. Subjective experiences of driving cessation and dementia: a meta-synthesis of qualitative literature. Clin Gerontol. 2020;43(2):135–54. https://doi.org/10.1080/07317115.2018.1483992 .
doi: 10.1080/07317115.2018.1483992
pubmed: 29863962
Stout SH, Babulal GM, Ma C, Carr DB, Head DM, Grant EA, et al. Driving cessation over a 24-year period: dementia severity and cerebrospinal fluid biomarkers. Alzheimers Dement. 2018;14(5):610–6. https://doi.org/10.1016/j.jalz.2017.11.011 .
doi: 10.1016/j.jalz.2017.11.011
pubmed: 29328928
pmcid: 5938126
Marshall GA, Sikkes SAM, Amariglio RE, Gatchel JR, Rentz DM, Johnson KA, et al. Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. Alzheimers Dement (Amst). 2020;12(1):e12118. https://doi.org/10.1002/dad2.12118 .
doi: 10.1002/dad2.12118
pubmed: 33163609
Snitz BE, Chang Y, Tudorascu DL, Lopez OL, Lopresti BJ, DeKosky ST, et al. Predicting resistance to amyloid-beta deposition and cognitive resilience in the oldest-old. Neurology. 2020;95(8):e984–94.
doi: 10.1212/WNL.0000000000010239
pubmed: 32699143
pmcid: 7668550
Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol. 2009;66(9):1151–7. https://doi.org/10.1001/archneurol.2009.106 .
doi: 10.1001/archneurol.2009.106
pubmed: 19752306
pmcid: 2863139
Thomas KR, Edmonds EC, Eppig JS, Wong CG, Weigand AJ, Bangen KJ, Jak AJ, Delano-Wood L, Galasko DR, Salmon DP, Edland SD, Bondi MW, Alzheimer’s Disease Neuroimaging Initiative. MCI-to-normal reversion using neuropsychological criteria in the Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement. 2019;15(10):1322–32. https://doi.org/10.1016/j.jalz.2019.06.4948 .
doi: 10.1016/j.jalz.2019.06.4948
pubmed: 31495605
pmcid: 6801026
Canevelli M, Grande G, Lacorte E, Quarchioni E, Cesari M, Mariani C, et al. Spontaneous Reversion of Mild Cognitive Impairment to Normal Cognition: A Systematic Review of Literature and Meta-Analysis. J Am Med Dir Assoc. 2016;17:943–8. https://doi.org/10.1016/J.JAMDA.2016.06.020 .
doi: 10.1016/J.JAMDA.2016.06.020
pubmed: 27502450